Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0037116 (silicosis)
1,822 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Respiratory infections of 19 subjects of advanced age and/or with underlying respiratory disease were treated with cefoperazone (CPZ) and its clinical effects were studied. Sixteen subjects suffered from respiratory tract infection and 3 subjects had pneumonia. The age of the subjects ranged from 39 to 77 years with the mean of 63.8, 7 of them being more than 70 years of age. The underlying respiratory diseases included chronic pulmonary emphysema in 6 subjects, diffuse panbronchiolitis in 3, bronchiectasis in 3, silicosis in 2 and one each of chronic bronchitis, pulmonary fibrosis, lung cancer and old pulmonary tuberculosis. One case, 75 years of age, had renal insufficiency. The daily dose of CPZ was 4 grams in 18 of the 19 subjects and the duration of administration ranged 5 to 22 days. The remaining 1 subject received 2 g of CPZ daily for 6 days. Clinical effects were judged from the changes in fever, cough, amount of sputum, dyspnea, rales, cyanosis, chest X-ray, white blood cell counts, CRP, erythrocyte sedimentation rates and results of sputum culture. Clinical effects were good in 16 subjects, fair in 1, and poor in 2. Bacteriological follow-up was carried out in 13 subjects. Infecting bacteria were eliminated from 5 subjects, reduced in 2 and, in 4 subjects, they were replaced by other bacteria. In 1 subject, P. aeruginosa was isolated from sputum even after the treatment with CPZ, and in another subject H. influenzae relapsed immediately after the cessation of the CPZ treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Effects of cefoperazone on respiratory infections of patients of advanced age and/or with underlying respiratory diseases]. 373 62

After a first infection with M. tuberculosis, reactivation of the disease may be prevented by chemoprophylaxis with isoniazid or rifampicin. Such chemoprophylaxis should be administered to all subjects with an immune defect due to HIV infection, immunosuppressors, severe diabetes, renal insufficiency or silicosis. Extensive sequelae of tuberculosis on chest X-ray are also a major risk of reactivation without treatment. Tuberculosis is most likely to become active during the first three years following first infection for an healthy subject. However, beyond this limit or when the time of infection is unknown, the most objective decisional analysis still demonstrates the clear-cut benefit of chemoprophylaxis in proportion to its side effects for all young subjects aged less than 35 years.
...
PMID:[Indications for chemoprophylaxis of tuberculosis. Arguments for]. 843 36